Evidence map›Paper›PMID 32257197›Full record

ArticleMolecular and clinical oncology2020

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer.

Helena Fohlin, Tove Bekkhus, Josefine Sandström, Tommy Fornander, Bo Nordenskjöld, John Carstensen, Olle Stål

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Salivary DNA methylation markers for cancer of oral cavity.Cancer biomarkers : section A of Disease markers · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Helena FohlinRegional Cancer Center Southeast Sweden, SE-581 85 Linköping, Sweden.
Tove BekkhusDepartment of Clinical and Experimental Medicine and Oncology, Linköping University, SE-581 83 Linköping, Sweden.
Josefine SandströmDepartment of Clinical and Experimental Medicine and Oncology, Linköping University, SE-581 83 Linköping, Sweden.
Tommy FornanderDepartment of Oncology, Karolinska University Hospital, Karolinska Institute, SE-171 77 Stockholm, Sweden.
Bo NordenskjöldDepartment of Clinical and Experimental Medicine and Oncology, Linköping University, SE-581 83 Linköping, Sweden.
John CarstensenDivision of Health and Society, Department of Medical and Health Sciences, Linköping University, SE-581 83 Linköping, Sweden.
Olle StålDepartment of Clinical and Experimental Medicine and Oncology, Linköping University, SE-581 83 Linköping, Sweden.
Linköping University · SEKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last few decades, improved and more individualized treatment has contributed to the increased survival rate of patients with breast cancer. However, certain patients may receive excessive treatment resulting in undesired side effects. In a previous study, it was demonstrated that systemically untreated patients with estrogen receptor (ER)-positive/progesterone receptor (PR)-negative tumors with high Ras-related protein Rab-6C (RAB6C) expression levels (RAB6C

Indexed as

breast neoplasmendocrine therapyhormone receptorsRAB6A'WTH3

Identifiers

PMID32257197
PMCPMC7087479
OpenAlexW3009783705

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.